mTOR inhibitors enhance killing of DLBCL cells by BH3 mimetics, such as venetoclax (ABT-199), ABT-263 or ABT-737.29 To evaluate the role of the 4E-BP/eIF4E axis in this sensitisation, we used a doxycycline (DOX)-inducible system to express wild-type 4E-BP1 or a constitutively active form in which all five serine/threonine phosphorylation sites were changed into alanine (5A mutant). Here, EIF4EBP1 is linked to diffuse large B-cell lymphoma.